Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Heart Failure Reviews Année : 2020

Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches

Résumé

Treatment of patients with heart failure with reduced ejection fraction (HFrEF) with currently available therapies reduces morbidity and mortality. However, implementation of these therapies is a problem with only few patients achieving guideline-recommended maximal doses of therapy. In an effort to improve guideline adherence and uptitration, several trials have investigated a biomarker-guided strategy (using natriuretic peptide targets in specific), but although conceptually promising, these trials failed to show a consistent beneficial effect on outcomes. In this review, we discuss different methodological issues that may explain the failure of these trials and offer potential solutions. Moreover, alternative approaches to increase heart failure guideline adherence are evaluated.
Fichier principal
Vignette du fichier
review_Failure NP-guided trials_HF.pdf (1.22 Mo) Télécharger le fichier
Loading...

Dates et versions

hal-02919808 , version 1 (24-08-2020)

Identifiants

Citer

Susan Stienen, Ankeet Bhatt, Joao Pedro Ferreira, Muthiah Vaduganathan, James Januzzi, et al.. Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. Heart Failure Reviews, 2020, 26 (1), pp.11-21. ⟨10.1007/s10741-020-10004-6⟩. ⟨hal-02919808⟩
33 Consultations
46 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More